Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes

Yamagishi, 2005, Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy, Curr. Pharm. Des., 11, 2279, 10.2174/1381612054367300 Brownlee, 2001, Biochemistry and molecular cell biology of diabetic complications, Nature, 414, 813, 10.1038/414813a 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, N. Engl. J. Med., 329, 977, 10.1056/NEJM199309303291401 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 2000, Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, N. Engl. J. Med., 342, 381, 10.1056/NEJM200002103420603 2003, Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study, JAMA, 290, 2159, 10.1001/jama.290.16.2159 Nathan, 2003, Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus, N. Engl. J. Med., 348, 2294, 10.1056/NEJMoa022314 Nathan, 2005, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, N. Engl. J. Med., 353, 2643, 10.1056/NEJMoa052187 Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N. Engl. J. Med., 359, 1577, 10.1056/NEJMoa0806470 Brownlee, 1988, Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications, N. Engl. J. Med., 318, 1315, 10.1056/NEJM198805193182007 Vlassara, 2002, Diabetes and advanced glycation endproducts, J. Intern. Med., 251, 87, 10.1046/j.1365-2796.2002.00932.x Takeuchi, 2009, Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease, J. Alzheimers Dis., 16, 845, 10.3233/JAD-2009-0974 Dyer, 1991, Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification glucose other carbohydrates as possible precursors pentosidine vivo, J Biol Chem, 266, 11654, 10.1016/S0021-9258(18)99007-1 Stern, 2002, Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings, Adv. Drug Deliv. Rev., 54, 1615, 10.1016/S0169-409X(02)00160-6 Bierhaus, 1998, AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus: I. The AGE concept, Cardiovasc. Res., 37, 586, 10.1016/S0008-6363(97)00233-2 Yamagishi, 2008, Agents that block advanced glycation end product (AGE)–RAGE (receptor for AGEs)–oxidative stress system: a novel therapeutic strategy for diabetic vascular complications, Expert Opin. Investig. Drugs, 17, 983, 10.1517/13543784.17.7.983 Yamagishi, 2008, Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication, Curr. Pharm. Des., 14, 487, 10.2174/138161208783597416 Takenaka, 2006, Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes, Curr. Neurovasc. Res., 3, 73, 10.2174/156720206775541804 Yamagishi, 2007, Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders, Curr. Mol. Med., 7, 463, 10.2174/156652407781387073 Frank, 1991, On the pathogenesis of diabetic retinopathy. A 1990 update, Ophthalmology, 98, 586, 10.1016/S0161-6420(91)32253-X Stitt, 1997, Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats, Am. J. Pathol., 150, 523 Yamagishi, 2002, Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes, Biochem. Biophys. Res. Commun., 290, 973, 10.1006/bbrc.2001.6312 Yamagishi, 2002, Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties, Biochem. Biophys. Res. Commun., 296, 877, 10.1016/S0006-291X(02)00940-3 Yamagishi, 2002, Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes, Mol. Med., 8, 546, 10.1007/BF03402164 Ottonello, 1995, Tumor necrosis factor-alpha-induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents, Br. J. Haematol., 91, 566, 10.1111/j.1365-2141.1995.tb05348.x Aiello, 1994, Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, N. Engl. J. Med., 331, 1480, 10.1056/NEJM199412013312203 Murata, 1995, Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels, Ophthalmic Res., 27, 48, 10.1159/000267567 Yamagishi, 2006, Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression, J. Biol. Chem., 281, 20213, 10.1074/jbc.M602110200 Anderson, 1997, Role of local and systemic angiotensin in diabetic renal disease, Kidney Int. Suppl., 63, S107 Yamagishi, 2003, Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation, Drugs Exp. Clin. Res., 29, 75 Amano, 2003, Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation, Int. J. Tissue React., 25, 51 Yamagishi, 2005, Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression, FEBS Lett., 579, 4265, 10.1016/j.febslet.2005.06.058 Tombran-Tink, 2003, PEDF: a multifaceted neurotrophic factor, Nat. Rev. Neurosci., 4, 628, 10.1038/nrn1176 Becerra, 2006, Focus on molecules: pigment epithelium-derived factor (PEDF), Exp. Eye Res., 82, 739, 10.1016/j.exer.2005.10.016 Ek, 2006, PEDF: a potential molecular therapeutic target with multiple anti-cancer activities, Trends Mol. Med., 12, 497, 10.1016/j.molmed.2006.08.009 Abe, 2007, Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma, Mini Rev Med Chem, 7, 649, 10.2174/138955707780859440 Yamagishi, 2008, Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications, Curr. Drug Targets, 9, 1025, 10.2174/138945008786786154 Yamagishi, 2005, Pigment epithelium-derived factor (PEDF) promotes growth of pericytes through autocrine production of platelet-derived growth factor-B, Microvasc. Res., 69, 128, 10.1016/j.mvr.2005.04.001 Yamagishi, 2005, Pigment epithelium-derived factor is a pericyte mitogen secreted by microvascular endothelial cells: possible participation of angiotensin II-elicited PEDF downregulation in diabetic retinopathy, Int. J. Tissue React., 27, 197 Hammes, 1991, Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy, Proc. Natl Acad. Sci. U.S.A., 88, 11555, 10.1073/pnas.88.24.11555 Stitt, 2002, The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes, Diabetes, 51, 2826, 10.2337/diabetes.51.9.2826 Kowluru, 2004, Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats, Diabetes, 53, 3233, 10.2337/diabetes.53.12.3233 Liu, 2004, Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site, Proc. Natl Acad. Sci. U.S.A., 101, 6605, 10.1073/pnas.0308342101 Zhang, 2006, Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF–VEGF receptor 2 binding in diabetic retinopathy, J. Mol. Endocrinol., 37, 1, 10.1677/jme.1.02008 Yamagishi, 2007, Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo, J. Int. Med. Res., 35, 896, 10.1177/147323000703500619 Jinnouchi, 2007, Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice, Brain Res., 1167, 92, 10.1016/j.brainres.2007.04.088 Funatsu, 2006, Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema, Ophthalmology, 113, 294, 10.1016/j.ophtha.2005.10.030 Schroder, 1991, Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy, Am. J. Pathol., 139, 81 Moore, 2003, The role of advanced glycation end products in retinal microvascular leukostasis, Invest Ophthalmol Vis Sci, 44, 4457, 10.1167/iovs.02-1063 Lu, 1999, VEGF increases retinal vascular ICAM-1 expression in vivo, Invest Ophthalmol Vis Sci, 40, 1808 Yamagishi, 2008, Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species, Ophthalmic Res., 40, 10, 10.1159/000111152 Inagaki, 2003, Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation, Diabetologia, 46, 284, 10.1007/s00125-002-1013-4 Mitamura, 2001, Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy, Ophthalmologica, 215, 415, 10.1159/000050900 Yamagishi, 2007, Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties, Protein Pept. Lett., 14, 832, 10.2174/092986607781483705 Yamagishi, 2006, Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis, Microvasc. Res., 72, 86, 10.1016/j.mvr.2006.04.002 Yamagishi, 2007, Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats, Ophthalmic Res., 39, 92, 10.1159/000099244 Zhang, 2006, Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor, FASEB J., 20, 323, 10.1096/fj.05-4313fje Yamagishi, 2005, Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells, Drugs Exp. Clin. Res., 31, 227 Hangaishi, 1998, Increased aggregation of human platelets produced by advanced glycation end products in vitro, Biochem. Biophys. Res. Commun., 248, 285, 10.1006/bbrc.1998.8945 Zoltowska, 2004, Impact of in vivo glycation of LDL on platelet aggregation and monocyte chemotaxis in diabetic psammomys obesus, Lipids, 39, 81, 10.1007/s11745-004-1205-7 Yamagishi, 1998, Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells, Diabetologia, 41, 1435, 10.1007/s001250051089 Nomura, 1995, Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes, J. Biol. Chem., 270, 28316, 10.1074/jbc.270.47.28316 Yamagishi, 1999, Insulin stimulates the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor, Microvasc. Res., 57, 329, 10.1006/mvre.1999.2145 Yamagishi, 1997, Advanced glycation end products-driven angiogenesis in vitro. Induction growth tube formation human microvascular endothelial cells autocrine vascular endothelial growth factor, J Biol Chem, 272, 8723, 10.1074/jbc.272.13.8723 Okamoto, 2002, Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin, FASEB J., 16, 1928, 10.1096/fj.02-0030fje Okamoto, 2002, Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro, Biochem. Biophys. Res. Commun., 297, 419, 10.1016/S0006-291X(02)02218-0 Miyata, 2002, Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms, J. Am. Soc. Nephrol., 13, 2478, 10.1097/01.ASN.0000032418.67267.F2 Yamagishi, 2008, Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression, Microvasc. Res., 75, 130, 10.1016/j.mvr.2007.05.001 Yamagishi, 2002, Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells, J. Biol. Chem., 277, 20309, 10.1074/jbc.M202634200 Yamagishi, 2007, Molecular mechanisms of diabetic nephropathy and its therapeutic intervention, Curr. Drug Targets, 8, 952, 10.2174/138945007781386884 de Vriese, 2001, Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes, J. Am. Soc. Nephrol., 12, 993, 10.1681/ASN.V125993 Schrijvers, 2006, A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat, Nephrol. Dial. Transplant., 21, 324, 10.1093/ndt/gfi217 Kim, 2005, Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy, Kidney Int., 67, 167, 10.1111/j.1523-1755.2005.00067.x Banba, 2000, Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy, Kidney Int., 58, 684, 10.1046/j.1523-1755.2000.00214.x Chiarelli, 2002, Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes, Diabetes Care, 25, 1829, 10.2337/diacare.25.10.1829 Ishibashi, Y., Matsui, T., Takeuchi, M., Yamagishi, S., Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression, Biochem Biophys Res Commun 391 1405–1408 Fukami, 2004, AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction, Kidney Int., 66, 2137, 10.1111/j.1523-1755.2004.66004.x Yamagishi, 2003, Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells, Kidney Int., 63, 464, 10.1046/j.1523-1755.2003.00752.x Ziyadeh, 2000, Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice, Proc. Natl Acad. Sci. U.S.A., 97, 8015, 10.1073/pnas.120055097 Suzuki, 1999, Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions, J. Am. Soc. Nephrol., 10, 822, 10.1681/ASN.V104822 Yang, 1994, Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease, Proc. Natl Acad. Sci. U.S.A., 91, 9436, 10.1073/pnas.91.20.9436 Vlassara, 1994, Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats, Proc. Natl Acad. Sci. U.S.A., 91, 11704, 10.1073/pnas.91.24.11704 Yamamoto, 2001, Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice, J. Clin. Invest., 108, 261, 10.1172/JCI11771 Wendt, 2003, RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy, Am. J. Pathol., 162, 1123, 10.1016/S0002-9440(10)63909-0 N. Reiniger, K. Lau, D. McCalla, B. Eby, B. Cheng, Y. Lu, W. Qu, N. Quadri, R. Ananthakrishnan, M. Furmansky, R. Rosario, F. Song, V. Rai, A. Weinberg, R. Friedman, R. Ramasamy, V. D'Agati,A.M. Schmidt, Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse, Diabetes 59 2043–2054 Forbes, 2002, Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy, Diabetes, 51, 3274, 10.2337/diabetes.51.11.3274 Thomas, 2005, Interactions between renin angiotensin system and advanced glycation in the kidney, J. Am. Soc. Nephrol., 16, 2976, 10.1681/ASN.2005010013 T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, S. Okuda, Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression, Pharmacol Res 61 34–39 M. Busch, S. Franke, C. Ruster, G. Wolf, Advanced glycation end-products and the kidney, Eur J Clin Invest 40 742–755 Fan, 2004, Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice, Nephrol. Dial. Transplant., 19, 3012, 10.1093/ndt/gfh499 Yamagishi, 2005, Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats, Drugs Exp. Clin. Res., 31, 45 Sebekova, 2003, Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products, J. Hum. Hypertens., 17, 265, 10.1038/sj.jhh.1001541 Saisho, 2006, Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan, Diab. Res. Clin. Pract., 74, 201, 10.1016/j.diabres.2006.04.015 Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N. Engl. J. Med., 345, 851, 10.1056/NEJMoa011303 Chang, 2004, Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway, Kidney Int., 65, 1664, 10.1111/j.1523-1755.2004.00602.x Yu, 2007, Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1, Toxicol. Sci., 96, 346, 10.1093/toxsci/kfm010 Tang, 2006, Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist, J. Am. Soc. Nephrol., 17, 1633, 10.1681/ASN.2005101113 Marx, 2004, Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products, Diabetes, 53, 2662, 10.2337/diabetes.53.10.2662 Wang, 2006, Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method, Chem Pharm Bull Tokyo, 54, 37, 10.1248/cpb.54.37 Yamagishi, 2008, Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation, Protein Pept. Lett., 15, 850, 10.2174/092986608785203746 Matsui, 2008, Telmisartan blocks advanced glycation end-product (AGE)-induced plasminogen activator inhibitor-1 gene expression in endothelial cells through activation of peroxisome proliferator-activated receptor-g, Lett Drug Des Dis, 5, 477, 10.2174/157018008786898590 Matsui, 2007, J. Int. Med. Res., 35, 482, 10.1177/147323000703500407 Yoshida, 2006, Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation, Diabetologia, 49, 3094, 10.1007/s00125-006-0437-7 Yoshida, 2008, Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation, J. Int. Med. Res., 36, 237, 10.1177/147323000803600204 Ma, 2007, Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by advanced glycation end products through activation of peroxisome proliferators-activated receptor gamma, J. Cardiovasc. Pharmacol., 49, 293, 10.1097/FJC.0b013e31803c5616 Matsui, 2009, Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation, Biochem. Biophys. Res. Commun., 385, 269, 10.1016/j.bbrc.2009.05.061 Wang, 2005, Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy, Diabetes, 54, 243, 10.2337/diabetes.54.1.243 Wang, 2006, Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities, Diabetes, 55, 1678, 10.2337/db05-1448 Maeda, 2011, Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)–receptor (RAGE) axis, Pharmacol. Res., 63, 241, 10.1016/j.phrs.2010.11.008 Ho, 2007, PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells, Cardiovasc. Res., 76, 213, 10.1016/j.cardiores.2007.06.032 Ho, 2008, Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma, Mol. Immunol., 45, 898, 10.1016/j.molimm.2007.08.004 Bolton, 2004, Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy, Am. J. Nephrol., 24, 32, 10.1159/000075627 Bucala, 1991, Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes, J. Clin. Invest., 87, 432, 10.1172/JCI115014 Bucala, 1995, Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor, J. Biol. Chem., 270, 10828, 10.1074/jbc.270.18.10828 Hoenig, 2008, Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1, Curr. Mol. Med., 8, 754, 10.2174/156652408786733685 Chen, 2009, Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2, Biochem. Biophys. Res. Commun., 381, 192, 10.1016/j.bbrc.2009.02.040 Scheubel, 2006, Depression of progenitor cell function by advanced glycation endproducts (AGEs): potential relevance for impaired angiogenesis in advanced age and diabetes, Exp. Gerontol., 41, 540, 10.1016/j.exger.2006.01.002 Bhatwadekar, 2008, Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy, Invest Ophthalmol Vis Sci, 49, 1232, 10.1167/iovs.07-1015 Chen, 2009, C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells, J. Cardiovasc. Pharmacol., 53, 359, 10.1097/FJC.0b013e31819b5438 Murohara, 1998, Nitric oxide synthase modulates angiogenesis in response to tissue ischemia, J. Clin. Invest., 101, 2567, 10.1172/JCI1560 H. Ueno, H. Koyama, S. Fukumoto, S. Tanaka, T. Shoji, T. Shoji, M. Emoto, H. Tahara, M. Inaba, R. Kakiya, T. Tabata, T. Miyata,Y. Nishizawa, Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease, Metabolism. Yamagishi, 1999, Advanced glycation endproducts accelerate calcification in microvascular pericytes, Biochem. Biophys. Res. Commun., 258, 353, 10.1006/bbrc.1999.0625 Shaw, 2003, S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2, Diabetes, 52, 2381, 10.2337/diabetes.52.9.2381 Sakaguchi, 2003, Central role of RAGE-dependent neointimal expansion in arterial restenosis, J. Clin. Invest., 111, 959, 10.1172/JCI200317115 Soro-Paavonen, 2008, Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes, Diabetes, 57, 2461, 10.2337/db07-1808 Asanuma, 2003, The role of podocytes in glomerular pathobiology, Clin. Exp. Nephrol., 7, 255, 10.1007/s10157-003-0259-6